Hypertension is regarded as the most prominent risk factor for cardiovascular diseases,
which have become a primary cause of death, and recent research has demonstrated that …

Objective: To develop an evidence-based guideline for the pharmacologic and
nonpharmacologic treatment of psoriatic arthritis (PsA), as a collaboration between the …

Psoriasis is a chronic, immune-mediated, inflammatory disease that is pathogenically driven
by proinflammatory cytokines. This article reviews the immunologic role of interleukin (IL)-17 …

Background Since the publication of the European League Against Rheumatism
recommendations for the pharmacological treatment of psoriatic arthritis (PsA) in 2012, new …

Psoriasis is a systemic inflammatory disease associated with increased risk of comorbidities,
such as psoriatic arthritis, Crohn's disease, malignancy, obesity, and cardiovascular …

Objective To assess the safety and efficacy of ixekizumab, a monoclonal antibody that
inhibits interleukin-17A, in a double-blind phase III trial enrolling patients with active …

Background Interleukin 17A is a proinflammatory cytokine that is implicated in the
pathogenesis of psoriatic arthritis. We assessed the efficacy and safety of subcutaneous …

Background In a phase 2 study, the inhibition of the interleukin-17A receptor improved signs
and symptoms of psoriatic arthritis. We sought to evaluate the efficacy and safety of …

Abstract The cytokine interleukin-12 (IL-12) was thought to have a central role in T cell–
mediated responses in inflammation for more than a decade after it was first identified …

Background Patients who have had inadequate response to tumour necrosis factor
inhibitors have fewer treatment options and are generally more treatment refractory to …